provera 200 mg tablet - 搜索结果

美国 - 英文 - NLM (National Library of Medicine)

depo-provera- medroxyprogesterone acetate injection, suspension

a-s medication solutions - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - depo-provera ci is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use depo-provera ci long-term [see warnings and precautions (5.1) ]. the use of depo-provera ci is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to depo-provera ci (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.7)] . - undiagnosed vaginal bleeding [see warnings a

美国 - 英文 - NLM (National Library of Medicine)

depo-provera- medroxyprogesterone acetate injection, suspension

a-s medication solutions - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - depo-provera ci is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use depo-provera ci long-term [see warnings and precautions (5.1) ]. the use of depo-provera ci is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to depo-provera ci (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.7)] . - undiagnosed vaginal bleeding [see warnings a

美国 - 英文 - NLM (National Library of Medicine)

depo-provera- medroxyprogesterone acetate injection, suspension

physicians total care, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone 400 mg in 1 ml - adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma. - known or suspected pregnancy or as a diagnostic test for pregnancy - undiagnosed vaginal bleeding - known or suspected malignancy of breast - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease - liver dysfunction or disease - known sensitivity to depo-provera (medroxyprogesterone acetate or any of its other ingredients).

美国 - 英文 - NLM (National Library of Medicine)

depo-provera- medroxyprogesterone acetate injection, suspension

pharmacia and upjohn company llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease - known sensitivity to depo-provera (medroxyprogesterone acetate or any of its other ingredients).